E
Evan A. Stein
Researcher at Medpace
Publications - 344
Citations - 38427
Evan A. Stein is an academic researcher from Medpace. The author has contributed to research in topics: Cholesterol & Familial hypercholesterolemia. The author has an hindex of 80, co-authored 340 publications receiving 36392 citations. Previous affiliations of Evan A. Stein include Cornell University & Memorial Hospital of South Bend.
Papers
More filters
Journal ArticleDOI
Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial.
TL;DR: Dalcetrapib showed no clinically relevant differences vs. placebo in adverse events, laboratory parameters including aldosterone, electrocardiograms, and vital signs including blood pressure (BP); and had no measurable, clinically relevant effect on lymph node size.
Journal ArticleDOI
Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
Peter B. Jones,Donald B. Hunninghake,Keith C. Ferdinand,Evan A. Stein,Alex Gold,Richard Caplan,James W. Blasetto +6 more
TL;DR: Rosuvastatin 10 to 40 mg was more efficacious in improving the lipid profile of patients with hypercholesterolemia than milligram-equivalent doses of atorvastatin and milligrams-equ equivalent or higher doses of simvastasin and pravastatin.
Journal ArticleDOI
Effects of high-dose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia
Adrian S. Dobs,Helmut G. Schrott,Michael H. Davidson,Harold Bays,Evan A. Stein,Deborah Kush,Mei Wu,Yale B. Mitchel,Roger D. Illingworth +8 more
TL;DR: There were small declines in the simvastatin-treated group for pooled total, free, and bioavailable testosterone after 12 weeks, although there was no compensatory increase in serum follicle-stimulating hormone (FSH) or luteinizing hormone (LH) levels.
Journal ArticleDOI
Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II
Christie M. Ballantyne,Marcelo Bertolami,Hugo Ricardo Hernandez Garcia,Daniel Nul,Evan A. Stein,Pierre Théroux,Robert M. Weiss,Valerie A. Cain,Joel S. Raichlen +8 more
TL;DR: Rosuvastatin 10 or 20 mg is an effective and safe therapeutic option for high-risk patients to achieve their lipid and apolipoprotein targets.
Journal ArticleDOI
Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers
Thomas M. van Himbergen,Nirupa R Matthan,Nancy A Resteghini,Seiko Otokozawa,Masumi Ai,Evan A. Stein,Peter B. Jones,Ernst J. Schaefer +7 more
TL;DR: In this paper, the effects of maximal doses of rosuvastatin with atorvastin and investigate the basis for the significant individual variation in lipid lowering response to statin therapy.